홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
NRXP
#4096
NRX Pharmaceuticals, Inc. Common Stock
2.525
0
USD
+1.00%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+1.00%
월간 변동
+30.83%
6달 변화
+41.85%
년간 변동율
+41.85%
이전 종가
2.500
0
Open
2.530
0
Bid
Ask
Low
2.520
0
High
2.550
0
양
185
마켓
주식
헬스케어
NRXP
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
Q4, 25
TTM
Key stats
Total common shares outstanding
33.07 M
—
Valuation ratios
Enterprise value
81.82 M
287.27 M
Price to earnings ratio
-2.03
-6.75
Price to sales ratio
47.35
—
Price to cash flow ratio
-4.11
-20.82
Price to book ratio
-3.64
-5.37
EBITDA 비율에 대한 기업 가치
-5.08
—
Profitability ratios
Return on assets %
0.03
-4.73
Return on equity %
-0.02
0.92
Return on invested capital %
-63.39
-245.85
Gross margin %
58.49
—
Operating margin %
-470.3
—
EBITDA margin %
-672.84
—
Net margin %
36.72
—
Liquidity ratios
Quick ratio
—
—
Current ratio
0.31
0.94
Inventory turnover
—
—
Asset turnover
0.07
0.09
Solvency ratios
Debt to assets ratio
0
3.89
Debt to equity ratio
0
-1.01
Long term debt to total assets ratio
0
3.89
Long term debt to total equity ratio
0
-1.01
Per share metrics
Operating cash flow per share
-0.17
-0.44
EBIT per share
-0.22
-0.51
EBITDA per share
-0.31
-0.51
Total debt per share
0
0.81
Cash per share
0.36
0.71
Net current asset value per share
0.42
1.03
Tangible book value per share
-0.87
-3.5
Working capital per share
-0.92
-3.57
Book value per share
-0.74
-3.26
뉴스
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript
NRx Pharmaceuticals, FDA 생동성 승인 통지 받아
NRx Pharmaceuticals receives FDA bioequivalence approval notice
NRx Pharmaceuticals, FDA로부터 NRX-100 신약 승인 관련 지침 받아
NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application
VTSAX vs. VTI: Which Vanguard Fund Should You Buy in 2026? - TipRanks.com
H.C. Wainwright, NRX 파마슈티컬 주가 목표 45달러로 상향
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer
NRx Builds Momentum From FDA Progress To Strategic Expansion - NRX Pharmaceuticals (NASDAQ:NRXP)
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/23/26 - TipRanks.com